ArticleNature2020
Structure of LRRK2 in Parkinson's disease and model for microtubule interaction.
Open access · greenAbstract read
In one paragraph
Article in Nature, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 131 papers.
0numbers the graph read from it
0cells of the map it votes in
131citing papers in PubMed
17.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
131 citing papers in PubMed, 242 citations in OpenAlex.
- Leucine-rich repeat kinase 2 (LRRK2): balancing cellular homeostasis and Parkinson's disease (PD) pathogenesis.Annals of medicine · 2026Review
- Article
- Molecular Docking of Natural Products: Critical Appraisal of Current Methodology and Practical Guidelines.Molecules (Basel, Switzerland) · 2026Review
- Constrained peptide mimics of the LRRK2 C-terminal Helix inhibits its kinase activity.Bioorganic chemistry · 2026Article
- PROTAC-Based Strategies in Neurodegenerative Diseases: Challenges and Perspectives.Pharmaceuticals (Basel, Switzerland) · 2026Review
- LRRK2: Molecular Mechanisms in Parkinson's Disease.International journal of molecular sciences · 2026Review
- Article
- R1398 is the GTP-γ-phosphate sensor that drives the ROC G-domain switching mechanism unique to Parkinson's disease-associated LRRK2.Research square · 2026Article
- Discovery of potent and selective LRRK2 inhibitors with preserved activity against the G2019S mutant via multi-stage virtual screening.Journal of computer-aided molecular design · 2026Article
- The structural basis for LRRK2's activation and autoinhibition.bioRxiv : the preprint server for biology · 2026Article
- Proximity proteomics reveals a co-evolved LRRK2-regulatory network linked to centrosomes.EMBO reports · 2026Article
- Elucidating the molecular interplay between LRRK2 and Rab GTPases.bioRxiv : the preprint server for biology · 2026Article
- Targeting of kinases to treat neurodegenerative diseases.Pharmacological reviews · 2026Review
- Discovery of Novel Chemotype LRRK2 Inhibitors Through AlphaFold2-Generated Structure-Based Docking Screen.International journal of molecular sciences · 2026Article
- Article
- LRRK2 kinase mediates increased GCase activity in microglia in response to IFNγ-induced proinflammatory stimulation.NPJ Parkinson's disease · 2026Article
- Role of LRRK2 in physiological activities, diseases, and therapy.Chinese medical journal · 2026Review
- Selective Stabilization of LRRK2 Kinase Conformations Reveals Distinct Modes of Action for Type I and II Inhibitors.Cell biochemistry and biophysics · 2026Article
- Targeting leucine-rich repeat kinase 2 overcomes resistance to oncolytic herpes simplex virus-based therapies in glioblastoma.Nature communications · 2026Article
- Structural and biochemical basis of ROC-dependent activation of LRRK2.Research square · 2026Article
71 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
14 authors at 6 institutions in 4 countries.
C K Deniston *Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA, USA.
J Salogiannis *Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA, USA.
S Mathea *Institute of Pharmaceutical Chemistry, Goethe-Universität, Frankfurt, Germany.
D M SneadDepartment of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA, USA.ORCID http://orcid.org/0000-0001-7839-452X
I LahiriDepartment of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA, USA.
M MatyszewskiDepartment of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA, USA.
O DonosaHoward Hughes Medical Institute, Chevy Chase, MD, USA.ORCID http://orcid.org/0000-0002-1871-447X
R WatanabeDivision of Biological Sciences, Molecular Biology Section, University of California San Diego, La Jolla, CA, USA.
J BöhningDivision of Biological Sciences, Molecular Biology Section, University of California San Diego, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-6242-1041
A K ShiauSmall Molecule Discovery Program, Ludwig Institute for Cancer Research, La Jolla, CA, USA.
S KnappInstitute of Pharmaceutical Chemistry, Goethe-Universität, Frankfurt, Germany.ORCID http://orcid.org/0000-0001-5995-6494
E VillaDivision of Biological Sciences, Molecular Biology Section, University of California San Diego, La Jolla, CA, USA.ORCID http://orcid.org/0000-0003-4677-9809
S L Reck-PetersonDepartment of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA, USA. sreckpeterson@ucsd.edu.ORCID http://orcid.org/0000-0002-1553-465X
A E LeschzinerDepartment of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA, USA. aleschziner@ucsd.edu.ORCID http://orcid.org/0000-0002-7732-7023
University of California San Diego · USHoward Hughes Medical Institute · USGoethe University Frankfurt · DEGenomics Institute of the Novartis Research Foundation · USIndian Institute of Science Education and Research Mohali · INLa Jolla Institute for Immunology · US
Funding
MOLECULAR BIOPHYSICS TRAINING PROGRAMT32GM008326 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI KOMIVES, ELIZABETH A. · 1989 to 2020
$7.5MRegulation of Cytoplasmic DyneinR01GM107214 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LESCHZINER, ANDRES · 2014 to 2021
$3.1MWest/Midwest Consortium for High-Resolution Cryo Electron MicroscopyU24GM116792 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI AGBANDJE-MCKENNA, MAVIS, DOKLAND, TERJE · 2016 to 2020
$3.0MOpening Windows into the Cell: Revealing the Molecular Architecture of the Nuclear PeripheryDP2GM123494 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI VILLA, ELIZABETH · 2016 to 2019
$2.5MCellular control of microtubule-based transport.R01GM121772 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI RECK-PETERSON, SAMARA L · 2017 to 2020
$1.6MHIGH-END CRYOEM INSTRUMENT FOR UCLA ELECTRON IMAGING CTR FOR NANOMACHINES: AIDSS10RR023057 · NCRR · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ZHOU, Z HONG · 2006 to 2006
$1.6MDirect Detection Device for atomic resolution cryoEM of macromolecular complexesS10OD018111 · OD · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ZHOU, Z HONG · 2014 to 2014
$598kHoward Hughes Medical InstituteNCRR NIH HHS S10 RR023057NIGMS NIH HHS DP2 GM123494NIGMS NIH HHS R01 GM107214NIGMS NIH HHS R01 GM121772NIGMS NIH HHS T32 GM008326NIGMS NIH HHS U24 GM116792NIH HHS S10 OD018111Wellcome Trust
Abstract
Leucine-rich repeat kinase 2 (LRRK2) is the most commonly mutated gene in familial Parkinson's disease
Indexed as
Cryoelectron MicroscopyAlkynesBenzamidesBiocatalysisDimerizationDyneinsHumansKinesinsLeucine-Rich Repeat Serine-Threonine Protein Kinase-2MicrotubulesModels, MolecularMovementParkinson DiseasePiperidinesProtein BindingProtein DomainsAlkynesBenzamidesDyneinsKinesinsLeucine-Rich Repeat Serine-Threonine Protein Kinase-2LRRK2 protein, humanolverembatinibPiperidinesPyrazolesPyridines
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.